Compositions and methods relating to reduction of symptoms of autism
AssigneeProthera, Inc.
InventorDevin B. Houston
Life of this patent
Estimating the term…
Abstract
Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.
Claims26
A composition for reducing the symptoms of autism in a human patient, comprising a physiologically effective amount of a purified casomorphin inhibitor that inhibits the opioid bioactivity of casomorphin by action of a casomorphinase which is a dipeptidyl peptidase, and a physiologically effective amount of a purified gluteomorphin inhibitor that inhibits the opioid bioactivity of gluteomorphin by action of a gluteomorphinase which is a phenylalaninase, and at least one of the group consisting of a physiologically acceptable carrier, adjuvant, excipient, buffer and diluent, wherein the composition decreases the incidence of one or more symptoms of autism selected from the group of symptoms consisting of eye contact avoidance, failure to socialize, attention deficit, poor mood, hyperactivity, anxiety, stimming, poor comprehension, inappropriate speech, abnormal sound sensitivity, poor digestion, disrupted sleep, and perseveration, and wherein the composition is suitable for oral administration and the decreased incidence is measured relative to the incidence in the untreated individual.
A method of reducing the symptoms of autism in a human patient, comprising orally administering to the patient a composition comprising a physiologically effective amount of a purified casomorphin inhibitor that inhibits the opioid bioactivity of casomorphin by action of a casomorphinase which is a dipeptidyl peptidase, and a physiologically effective amount of a purified gluteomorphin inhibitor that inhibits the opioid bioactivity of gluteomorphin by action of a gluteomorphinase which is a phenylalaninase, and at least one of the group consisting of a physiologically acceptable carrier, adjuvant, excipient, buffer and diluent, wherein the composition decreases the incidence of one or more symptoms of autism selected from the group of symptoms consisting of eye contact avoidance, failure to socialize, attention deficit, poor mood, hyperactivity, anxiety, stimming, poor comprehension, inappropriate speech, abnormal sound sensitivity, poor digestion, disrupted sleep, and perseveration, and wherein the composition is suitable for oral administration and the decreased incidence is measured relative to the incidence in the untreated individual.
A method of manufacturing a medicament for reducing the symptoms of autism in a human patient, comprising combining physiologically effective amount of a purified casomorphin inhibitor that inhibits the opioid bioactivity of casomorphin by action of a casomorphinase which is a dipeptidyl peptidase, and a physiologically effective amount of a purified gluteomorphin inhibitor that inhibits the opioid bioactivity of gluteomorphin by action of a gluteomorphinase which is a phenylalaninase, and at least one of the group consisting of a physiologically acceptable carrier, adjuvant, excipient, buffer and diluent, wherein the medicament decreases the incidence of one or more symptoms of autism selected from the group of symptoms consisting of eye contact avoidance, failure to socialize, attention deficit, poor mood, hyperactivity, anxiety, stimming, poor comprehension, inappropriate speech, abnormal sound sensitivity, poor digestion, disrupted sleep, and perseveration, and wherein the composition is suitable for oral administration and the decreased incidence is measured relative to the incidence in the untreated individual.
Dependencies are inferred from the claim text.